Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in Active Ankylosing Spondylitis (Biologic-Experienced)
NCT04483687Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in ankylosing spondylitis (AS) (5 arms), sponsored by Gilead Sciences. Primary endpoint: Assessment of SpondyloArthritis international Society 40% Improvement at 16 weeks. Planned start Dec 2020; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04483687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483687.